Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.
Baronciani L, Peake I, Schneppenheim R, Goodeve A, Ahmadinejad M, Badiee Z, Baghaipour MR, Benitez O, Bodó I, Budde U, Cairo A, Castaman G, Eshghi P, Goudemand J, Hassenpflug W, Hoorfar H, Karimi M, Keikhaei B, Lassila R, Leebeek FWG, Lopez Fernandez MF, Mannucci PM, Marino R, Nikšić N, Oyen F, Santoro C, Tiede A, Toogeh G, Tosetto A, Trossaert M, Zetterberg EMK, Eikenboom J, Federici AB, Peyvandi F. Baronciani L, et al. Among authors: hoorfar h. Blood Adv. 2021 Aug 10;5(15):2987-3001. doi: 10.1182/bloodadvances.2020003397. Blood Adv. 2021. PMID: 34351388 Free PMC article.
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.
Tosetto A, Badiee Z, Baghaipour MR, Baronciani L, Battle J, Berntorp E, Bodó I, Budde U, Castaman G, Eikenboom JCJ, Eshghi P, Ettorre C, Goodeve A, Goudemand J, Hay CRM, Hoorfar H, Karimi M, Keikhaei B, Lassila R, Leebeek FWG, Lopez Fernandez MF, Mannucci PM, Mazzucconi MG, Morfini M, Oldenburg J, Peake I, Parra Lòpez R, Peyvandi F, Schneppenheim R, Tiede A, Toogeh G, Trossaert M, Zekavat O, Zetterberg EMK, Federici AB. Tosetto A, et al. Among authors: hoorfar h. J Thromb Haemost. 2020 Sep;18(9):2145-2154. doi: 10.1111/jth.14886. Epub 2020 Aug 25. J Thromb Haemost. 2020. PMID: 32379400 Free article.
Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients.
Abolghasemi H, Panahi Y, Ahmadinejad M, Toogeh G, Karimi M, Eghbali A, Mirbehbahani NB, Dehdezi BK, Badiee Z, Hoorfar H, Eshghi P, Maghsoudi N, Sahebkar A, Gholami-Fesharaki M. Abolghasemi H, et al. Among authors: hoorfar h. J Pharmacopuncture. 2018 Jun;21(2):76-81. doi: 10.3831/KPI.2018.21.009. Epub 2018 Jun 30. J Pharmacopuncture. 2018. PMID: 30151307 Free PMC article.
Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients.
Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Subramanian K, D'Souza F, Viswabandya A, Hoorfar H, Schwartz BA, Solomon C, Knaub S, Peyvandi F. Lissitchkov T, et al. Among authors: hoorfar h. J Thromb Haemost. 2020 Apr;18(4):815-824. doi: 10.1111/jth.14727. Epub 2020 Jan 21. J Thromb Haemost. 2020. PMID: 31885190 Free PMC article.
A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.
Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Vaziri B, Kamyar K, Heshmat R, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M. Faranoush M, et al. Among authors: hoorfar h. Clin Appl Thromb Hemost. 2016 Mar;22(2):184-90. doi: 10.1177/1076029614555902. Epub 2014 Oct 24. Clin Appl Thromb Hemost. 2016. PMID: 25343955 Free article. Clinical Trial.
Thalassemia in Iran: epidemiology, prevention, and management.
Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H. Abolghasemi H, et al. Among authors: hoorfar h. J Pediatr Hematol Oncol. 2007 Apr;29(4):233-8. doi: 10.1097/MPH.0b013e3180437e02. J Pediatr Hematol Oncol. 2007. PMID: 17414565
A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.
Faranoush M, Abolghasemi H, Toogeh G, Karimi M, Eshghi P, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Kamyar K, Heshmat R, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M. Faranoush M, et al. Among authors: hoorfar h. Clin Appl Thromb Hemost. 2015 Nov;21(8):724-8. doi: 10.1177/1076029614522545. Epub 2014 Mar 19. Clin Appl Thromb Hemost. 2015. PMID: 24651301 Free article. Clinical Trial.
Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran.
Golestani M, Eshghi P, Rasekh HR, Cheraghali AM, Salamzadeh J, Naderi M, Managhchi MR, Hoorfar H, Toogeh GR, Imani A, Khodayari MT, Habibpanah B, Hantooshzadeh R. Golestani M, et al. Among authors: hoorfar h. Iran J Pharm Res. 2016 Spring;15(2):669-77. Iran J Pharm Res. 2016. PMID: 27642341 Free PMC article.
14 results